Table 2.
Treatments of lung cancer patients
| Treatments n = 112 (100%) | N (%) |
|---|---|
| Surgery, n (%) 62 (55) | 62 (100) |
| Elective | 60 (97) |
| Revision | 3 (5) |
| Emergency | 2 (3) |
| Radiation (Rad), n (%) 56 (50) | 56 (100) |
| Thorax | 45 (80) |
| Brain | 14 (25) |
| Skeleton | 7 (13) |
| Chemotherapy, n (%) 69 (62) | 69 (100) |
| Platinum compounds | 58 (84) |
| Vinorelbine | 32 (46) |
| Pemetrexed | 18 (26) |
| Taxanes | 16 (23) |
| Etoposide | 9 (13) |
| Gemicitabine | 2 (3) |
| Bisphosphonates | 11 (16) |
| Targeted, n (%) 47 (42) | 47 (100) |
| Kinase inhibitors | 15 (32) |
| Immune checkpoint inhibitors | 33 (70) |
| Viscum album L. (VA), n (%) 53 (47) | 53 (100) |
| Subcutaneous | 49 (92) |
| Intravenous | 35 (66) |
| Intra-tumoural/-pleural | 3 (6) |
The numbers in rows and columns of treatments applied to patients do not necessarily add to one hundred percent as patients may have received various combinations of preparations. N numbers